HomeCompareALID vs ABBV

ALID vs ABBV: Dividend Comparison 2026

ALID yields 400000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ALID wins by $5.011119029548644e+32M in total portfolio value
10 years
ALID
ALID
● Live price
400000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.011119029548644e+32M
Annual income
$500,865,583,351,836,840,000,000,000,000,000,000,000.00
Full ALID calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ALID vs ABBV

📍 ALID pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALIDABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALID + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALID pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALID
Annual income on $10K today (after 15% tax)
$34,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$425,735,745,849,061,300,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ALID beats the other by $425,735,745,849,061,300,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALID + ABBV for your $10,000?

ALID: 50%ABBV: 50%
100% ABBV50/50100% ALID
Portfolio after 10yr
$2.505559514774322e+32M
Annual income
$250,432,791,675,918,420,000,000,000,000,000,000,000.00/yr
Blended yield
99.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ALID
No analyst data
Altman Z
-48.1
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALID buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALIDABBV
Forward yield400000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$5.011119029548644e+32M$102.3K
Annual income after 10y$500,865,583,351,836,840,000,000,000,000,000,000,000.00$24,771.77
Total dividends collected$5.010957816668433e+32M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ALID vs ABBV ($10,000, DRIP)

YearALID PortfolioALID Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$40,010,700$40,000,000.00$11,550$430.00+$40.00MALID
2$149,615,521,729$149,572,710,280.37$13,472$627.96+$149615.51MALID
3$522,880,052,725,200$522,719,964,116,949.25$15,906$926.08+$522880052.71MALID
4$1,707,862,989,289,045,000$1,707,303,507,632,628,700.00$19,071$1,382.55+$1707862989289.03MALID
5$5,213,509,402,845,684,000,000$5,211,681,989,447,144,000,000.00$23,302$2,095.81+$5213509402845684.00MALID
6$14,874,219,058,409,543,000,000,000$14,868,640,603,348,497,000,000,000.00$29,150$3,237.93+$14874219058409543680.00MALID
7$39,661,196,234,050,755,000,000,000,000$39,645,280,819,658,260,000,000,000,000.00$37,536$5,121.41+$3.966119623405075e+22MALID
8$98,838,436,350,327,300,000,000,000,000,000$98,795,998,870,356,880,000,000,000,000,000.00$50,079$8,338.38+$9.88384363503273e+25MALID
9$230,205,236,474,344,900,000,000,000,000,000,000$230,099,479,347,450,050,000,000,000,000,000,000.00$69,753$14,065.80+$2.302052364743449e+29MALID
10$501,111,902,954,864,400,000,000,000,000,000,000,000$500,865,583,351,836,840,000,000,000,000,000,000,000.00$102,337$24,771.77+$5.011119029548644e+32MALID

ALID vs ABBV: Complete Analysis 2026

ALIDStock

Allied Corp., a medical cannabis production company, engages in the research, development, and production of cannabinoid health solutions in the United States. It offers hemp-derived natural health products, including Liberty, a hemp-derived cannabidiol (CBD) tincture; Tactical Hydration, a CBD infused electrolyte replacement drink; FIZZ Tablets for adding in a water bottle; Battle Balm, a CBD roll on activity rub for aches and pains; and Quick Hit, a CBD gummy under the Tactical Relief brand. The company also provides Hydrosport CBD Drink, a CBD infused electrolyte replacement drink with sodium citrate electrolyte replacement; Hydrosport Tincture, a CBD tincture fortified with specific terpene profile; FIZZ Tablets for adding to a water bottle; Sport Rub, a CBD post-activity rub for aches and pains; and Quick Hit, a CBD gummy with vitamin B12 under the Equilibrium Bio brand. In addition, it offers Skin Structure, a facial formula topically applied to enhance skin's radiance and youthfulness; Eye Recover that helps the eye skin ward off free radicals, as well as helping to protect against sun damage; Glossy Lip Recover, which moisturizes and nourishes lips; Skin Designer that stimulates cell regeneration while minimizing age spots; Vitamin Absolute, a moisturizing facial oil; and Absolute Recover, a formulation that allows the infused bioactive compounds to be delivered directly to the desired areas of inflammation, pain, and other skin ailments under the MaXXa brand. In addition, it is developing ALID 10 and ALID 11, a pharma product, which is in Phase I clinical trial for treating post-traumatic stress disorder. The company was incorporated in 2013 and is headquartered in Kelowna, Canada.

Full ALID Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ALID vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALID vs SCHDALID vs JEPIALID vs OALID vs KOALID vs MAINALID vs JNJALID vs MRKALID vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.